Shares of Ultragenyx surged 14% to $29.91 after the FDA granted accelerated approval for the company's first-ever gene therapy, a one-time treatment for a rare liver disorder that prevents the body from converting stored sugar into usable glucose. The milestone marks a strategic turning point — but investors must weigh a very small addressable population against the stock's sudden enthusiasm.
A First-of-Its-Kind Treatment, Built on Solid Trial Data. The approval rests on the Phase 3 GlucoGene study of 46 patients, which showed a statistically significant reduction in daily cornstarch intake — the grueling around-the-clock dietary regimen patients use to stay alive — versus placebo (p<0.001).
At 96 weeks, the treated groups showed a 61% reduction from baseline. There is no competing approved therapy for this condition, giving Ultragenyx a monopoly — at least for now. However, as a condition of accelerated approval, Ultragenyx must provide two years of real-world data from 50 treated patients and 20 controls , meaning full confirmation of the drug's benefit is still pending.
The Patient Pool Is Razor-Thin. An estimated 6,000 patients worldwide are affected by GSDIa , and the U.S. population is roughly 1,500–2,500 people, according to company estimates. Gene therapies for ultra-rare diseases routinely carry price tags of $2–3 million per dose — comparable treatments like Zynteglo and Zolgensma are priced at $2.8 million and $2.1 million, respectively. Even at those levels, maximum U.S. revenue potential likely caps in the low hundreds of millions, making this a meaningful but not transformational revenue driver on its own.
The Bonus Check and What Comes Next. Ultragenyx also received a Priority Review Voucher — a transferable ticket that speeds up FDA review of a future drug — valued at roughly $200 million if sold. Management has said it intends to sell vouchers from both this and an upcoming approval to raise "incremental non-dilutive capital."
A second gene therapy targeting Sanfilippo syndrome faces a September PDUFA decision , making the next 30 days critical. Ultragenyx reaffirmed 2026 revenue guidance of $730–760 million and remains on track for profitability in 2027.
Why $29.91 Still Demands Scrutiny. Even after the jump, shares remain 34% below their 52-week high , and analysts peg fair value near $52.
Conservative modeling suggests $1.5–2.4 billion in peak annual revenue from late-stage programs. The approval validates Ultragenyx's gene-therapy engine, but with a ~$2.6 billion market cap, the stock's real inflection depends on whether the September decision — and Angelman syndrome data later this year — deliver a second and third act.